Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data

2026-01-08 17:45:37 ET

The last time I spoke about Immuneering Corporation ( IMRX ) it was in a Seeking Alpha article entitled "Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst." With respect to this article, I mentioned that this company was able to release positive data from its phase 2a study using its drug atebimetinib + modified gemcitabine/nab-paclitaxel [mGnP] to treat patients with 1st-line pancreatic cancer. There was a landmark 83% overall-survival [OS] observed at 9 months....

Read the full article on Seeking Alpha

For further details see: